Drug Trial Radar · NCT05917340
Intensified Short Course Regimen for TBM in Adults
Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
372
Planned (sponsor's estimate)
Start
Mar 2024
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Indian Council of Medical ResearchGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- All India Institute of Medical Sciences, Jodhpur; Christian Medical College, Vellore, India; Jawaharlal Institute of Postgraduate Medical Education & Research; North Eastern Indira Gandhi Regional Institute of Health ans Medical Sciences; Madras Medical College; Rural Development Trust Hospital
- First posted
- Jun 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tuberculous meningitis (TBM) is the most lethal form of extra pulmonary tuberculosis. This devastating disease kills almost a third of its sufferers and disables a significant proportion of the survivors. TBM poses one of the most difficult diagnostic and therapeutic challenges in modern clinical practice. High-quality robust clinical trials have made a considerable contribution to the treatment of pulmonary tuberculosis in the last four decades. However, evidence from such clinical trials is lacking in TBM and the treatment remains uncertain. There is a significant variation in the choice, dose and duration of drugs between countries, institutions and clinicians. Investigators propose a multi-centric open-label clinical trial to assess the efficacy of short-course anti-TB drugs with high dose rifampicin, and moxifloxacin along with conventional anti-TB drugs and adjuvant therapy with aspirin and corticosteroids. Controls will receive standard treatment as per national guidelines for TBM. The investigators also aim to assess the safety and tolerability of high-dose Rifampicin and Moxifloxacin and the Pharmacodynamics and Pharmacokinetics parameters of ATT (Rifampicin, INH, Moxifloxacin and Pyrazinamide) in CSF between the two groups
Conditions
- Tuberculous Meningitis
Interventions
High dose rifampicin (25mg/kg)Drug
Given for 2 months
Moxifloxacin 400mgDrug
Given for 2 months
Aspirin 150 mgDrug
Given for 2 months
IsoniazidDrug
Given for 6 months
PyrazinamideDrug
Given for 6 months
SteroidDrug
Tapering dose of dexamethasone or prednisolone upto 8 weeks
RifampicinDrug
Standard dose for 4 months after the initial treatment with high dose
HRZEDrug
2 months
HREDrug
7-10 months as per TB program guidelines
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality rateTime frame: 12 months
- Disability rateTime frame: 12 months
- Mortality rateTime frame: 12 months
- Disability rateTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICMR- National Institute for Research in Tuberculosis
Chennai, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.